Unlearn

What is Unlearn?

Unlearn is an AI company for clinical trials. Its core technology is the digital twin, an AI-generated forecast of one participant's clinical outcomes. Trial sponsors use these twins to make design and analysis decisions across a study's lifecycle, and the vendor positions itself as an AI partner for pharma and biotech.

Key capabilities of Unlearn

• Patient digital twins: Forecasts of individual participant outcomes.
• Design-stage modeling: Tests eligibility, endpoints and sample size before protocol lock.
• Interim analysis support: Pre-specified twin analyses for decisions during a study.
• Post-readout re-analysis: Extracts more information per participant from completed data.
• Single-arm study support: Adds context to studies without a control arm.

How Unlearn works

Sponsors supply trial and historical data, and Unlearn builds twins of expected or enrolled participants. In design, the twins model expected enrollees to test choices before protocol lock. During a study, pre-specified twin analyses can inform interim decisions, and after readout the data can be re-analyzed.

Who uses Unlearn?

Pharmaceutical and biotech sponsors running clinical trials. The vendor names Trace Neuroscience, QurAlis, remynd, Acumen Pharmaceuticals, SOLA Biosciences and VectorY Therapeutics among partners.

Unlearn pricing

Unlearn does not disclose pricing. Visitors are directed to contact the company.

Unlearn alternatives

Insilico Medicine uses generative AI mainly for drug discovery and target identification, which comes earlier than trial design. Deep 6 AI uses clinical data to match patients to trials, which addresses recruitment rather than outcome forecasting. LatchBio provides a platform for running bioinformatics workflows for biotech teams.